ViewPoint Therapeutics – $35 Million Series B
Palo Alto – April 13, 2018 – Cooley advised ViewPoint Therapeutics on closing its $35 million Series B funding round led by TPG’s new $2 billion social impact fund, The Rise Fund. Cooley partner Mehdi Khodadad led the team advising ViewPoint on the financing.
The round also included participation from Novo Holdings and existing investors Biotechnology Value Fund, Mission Bay Capital, Lagunita BioSciences and the University of Michigan through its MINTS initiative, which is part of the endowment’s venture capital portfolio, and Ed Hurwitz, co-founder and chairman of ViewPoint. ViewPoint plans to use the proceeds of the financing to develop its lead product candidate, VP1-001, through clinical proof-of-concept studies in patients with cataracts and presbyopia. It also anticipates the proceeds will allow it to advance second-generation compounds from its ongoing medicinal chemistry efforts.
“Cataracts remain the world’s leading cause of blindness, and this financing will meaningfully advance our efforts to develop and commercialize a groundbreaking treatment,” said Leah Makley, ViewPoint co-founder and CEO, in a news release.
ViewPoint is a preclinical-stage biotechnology company passionately committed to the discovery, development and commercialization of treatments for diseases of protein misfolding, which is implicated in numerous common disorders of aging, including cataracts and presbyopia.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900+ lawyers across 13 offices in the United States, China and Europe.
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.